Discontinued Product

Pyroxamide (Cat. No. 4403) has been withdrawn from sale for commercial reasons.
Description: Histone deacetylase inhibitor
Chemical Name: N-Hydroxy-N'-3-pyridinyloctanediamide
Purity: ≥98% (HPLC)
Citations (1)
Reviews (1)
Literature (4)

Biological Activity for Pyroxamide

Pyroxamide is an inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells.

Technical Data for Pyroxamide

M. Wt 265.31
Formula C13H19N3O3
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 382180-17-8
PubChem ID 4996

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for Pyroxamide

References are publications that support the biological activity of the product.

Butler et al (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin.Cancer Res. 7 962 PMID: 11309347

Remiszewski et al (2002) Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J.Med.Chem. 45 755 PMID: 11831887

Bradner et al (2010) Chemical phylogenetics of histone deacetylases. Nat.Chem.Biol. 6 238 PMID: 20139990

Carrillo et al (2015) Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). Bioorg.Med.Chem. 23 5151 PMID: 25637120

View Related Products by Product Action

View all Class I HDAC Inhibitors

Keywords: Pyroxamide, Pyroxamide supplier, Pyroxamide, hdac, histone, deacetylase, inhibitors, inhibits, epigenetics, Class, I, HDACs, 4403, Tocris Bioscience

1 Citation for Pyroxamide

Citations are publications that use Tocris products. Selected citations for Pyroxamide include:

Kim (2018) Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition. Br J Cancer 118 1359 PMID: 29695769

Reviews for Pyroxamide

Average Rating: 5 (Based on 1 Review.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Pyroxamide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

TGF beta high responder treated with 1.5 μM Pyroxamide (HDAC 1 inhibitor) for 48 h. Cell lysates were analysed by western blot..
By Anonymous on 11/15/2019
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: C3-TAg tumour cell

TGF beta high responder treated with 1.5 μM Pyroxamide (HDAC 1 inhibitor) for 48 h. Cell lysates were analysed by western blot.

PMID: 29695769
review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.